Expanded/​Activated Gamma Delta T-cell Infusion

Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

What's the purpose of the trial?

Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partially mismatched bone marrow transplant (haploidentical).
Trial status

Accepting patients

Phase
Phase 1
Enrollment
38
Last Updated
2 months ago
Am I Eligible

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • EAGD (Expanded/Activated Gamma Delta) T-cells are T-cells that are removed and genetically modified to help them recognize and kill cancer cells in the body.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

EAGD T-cell infusion

Accepting patients

EAGD T-cell infusion (Expansion)

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.